10-Q: Heartflow Fights CAD with Strong Revenue Growth, Faces Legal Headwinds

Heartflow, Inc. reports a 57% year-over-year revenue increase for Q3 2026, driven by product adoption and expanded reimbursement, while navigating significant legal investigations and patent litigation.

Summary

• Heartflow, Inc. reported a 57% increase in revenue for the three months ended September 30, 2026, reaching $72.9 million, compared to $46.3 million in the prior year period.
• For the nine months ended September 30, 2026, revenue grew 49% to $189.5 million, up from $126.9 million in the same period last year.
• Gross margin improved to 84% in Q3 2026 from 77% in Q3 2025, and to 82% for the nine-month period from 76% in the prior year.
• Net loss for Q3 2026 was $11.5 million, an improvement from $50.9 million in Q3 2025. For the nine months, net loss was $54.6 million, down from $92.4 million.
• The company has $253.0 million in cash, cash equivalents, and investments as of September 30, 2026, which management believes is sufficient for at least the next 12 months.
• Significant legal proceedings are ongoing, including a DOJ investigation under the Anti-Kickback Statute and Civil False Claims Act, and patent infringement lawsuits against Cleerly, Inc. and Elucid Bioimaging Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong revenue growth and improving gross margins, but ongoing net losses and significant legal risks.

Positives

• Revenue increased by 57% to $72.9 million for the three months ended September 30, 2026, compared to $46.3 million in the prior year.
• Revenue for the nine months ended September 30, 2026, increased by 49% to $189.5 million, up from $126.9 million in the prior year.
• Gross margin improved to 84% in Q3 2026 from 77% in Q3 2025, indicating improved operational efficiency.
• Net loss for Q3 2026 decreased significantly to $11.5 million from $50.9 million in Q3 2025.
• The company's cash, cash equivalents, and investments totaled $253.0 million as of September 30, 2026, providing a solid liquidity position.
• Heartflow Plaque Analysis adoption is increasing, driven by expanded reimbursement coverage.
• Revenue case volume increased by 89% year-over-year for Q3 2026.

Negatives

• The company continues to incur significant net losses, with a net loss of $11.5 million in Q3 2026 and $54.6 million for the nine months ended September 30, 2026.
• An asset impairment charge of $7.5 million was recognized in March 2026 related to the Mountain View facility sublease.
• Selling, general, and administrative expenses increased by 36% for Q3 2026 and 38% for the nine-month period, reflecting increased operational costs.
• The company faces ongoing legal proceedings, including a DOJ investigation and patent infringement lawsuits, which could have a material adverse impact.
• Average selling price decreased due to a higher percentage of revenue cases from clinic/office-based accounts and increased volume rebates.

Risks

• Ongoing U.S. Department of Justice investigation under the federal Anti-Kickback Statute and Civil False Claims Act, with potential material impact on business, results of operations, financial condition, or cash flows.
• Patent infringement lawsuit filed against Cleerly, Inc. and Elucid Bioimaging Inc., which could result in significant damages or injunctive relief.
• A putative class action and PAGA matter filed by an employee alleging violations of California labor laws.
• Dependence on the success of Heartflow FFR CT Analysis and Heartflow Plaque Analysis products.
• Potential negative impact if healthcare providers are unwilling to change standard practices or if third-party payors do not provide adequate reimbursement.
• Competition in an environment of rapid technological change.
• Risks associated with the use and development of AI models.
• Failure to obtain and maintain sufficient intellectual property rights.

Future Outlook

The company expects to continue incurring losses and significant cash expenditures in the foreseeable future due to business scaling, R&D investment, sales and marketing expansion, and increased G&A for public company operations. Management believes current cash, equivalents, and investments, along with expected revenue, will be sufficient for at least the next 12 months, but may need to raise additional capital.

Management Comments

• We believe that the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the CCTA + Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD.
• We have experienced considerable revenue growth since we began commercializing the Heartflow Platform in 2015, driven primarily by growth in our account base and increasing test volumes at accounts in our installed base.
• We expect our research and development expenses to increase as we conduct clinical studies for expanded indications for use or to expand the addressable market populations for our products and to hire additional personnel to develop new product offerings and product enhancements.
• We expect that our selling, general and administrative expenses will increase in the future as a result of expanding our operations, including hiring personnel, to both drive and support anticipated growth as well as various incremental costs associated with operating as a public company.

Industry Context

StockSavvy.ai notes that Heartflow operates in the rapidly evolving medical technology sector, specifically focusing on non-invasive diagnostics for coronary artery disease. The company's use of AI and computational fluid dynamics positions it at the forefront of innovation, aiming to set a new standard of care. The increasing adoption of its Plaque Analysis product, supported by expanded reimbursement, indicates a positive market reception for advanced diagnostic tools.

Comparison to Industry Standards

• Heartflow's revenue growth of 57% year-over-year in Q3 2026 and 49% for the nine-month period significantly outpaces the typical growth rates seen in many established medical device companies, suggesting strong market penetration.
• The improvement in gross margin to 84% in Q3 2026 is a positive indicator, though direct comparisons are difficult without specific segment data from competitors like GE Healthcare, Siemens Healthineers, or Philips in their diagnostic imaging software divisions.
• The company's net loss, while substantial, is common for growth-stage medical technology firms investing heavily in R&D and commercial expansion, a pattern seen in companies like Butterfly Network or Guardant Health during their growth phases.
• Heartflow's focus on AI-driven diagnostics aligns with a broader industry trend towards leveraging artificial intelligence to improve diagnostic accuracy and efficiency, a direction pursued by various startups and established players in medical imaging and diagnostics.

Legal Proceedings

• U.S. Department of Justice investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
• Patent infringement lawsuit filed against Cleerly, Inc.
• Patent infringement lawsuit filed against Elucid Bioimaging Inc.
• Putative class action and PAGA matter filed by an employee in California.

Stakeholder Impact

• Shareholders: Continued net losses and ongoing legal risks may impact stock price and investor confidence, while revenue growth and improved margins offer positive long-term potential.
• Employees: Increased R&D and SG&A expenses suggest continued hiring and investment in personnel, potentially leading to growth opportunities.
• Customers (Healthcare Providers): The company's products aim to improve CAD diagnosis and management, potentially leading to better patient outcomes and more efficient clinical workflows.
• Payors: Expanded reimbursement coverage for Heartflow Plaque Analysis is a positive development, but ongoing payor coverage decisions remain critical for adoption.

Next Steps

• Continue to drive adoption of Heartflow FFR CT Analysis and Heartflow Plaque Analysis.
• Launch Heartflow Plaque Tracker in 2027.
• Enroll patients in three randomized clinical trials focused on high-risk asymptomatic subpopulations.
• Expand international presence beyond current markets.
• Continue to invest in R&D for expanded indications and new product offerings.
• Manage ongoing legal proceedings and investigations.

Key Dates

Recommendation

Heartflow demonstrates strong revenue growth and improving gross margins, indicating positive commercial traction. However, the significant ongoing net losses, substantial operating expenses, and material legal risks (DOJ investigation, patent litigation, class action) warrant a cautious approach. While the company's technology is innovative, the uncertainties surrounding the legal matters and the path to profitability suggest a 'hold' rating until these risks are better understood and mitigated.

Keywords

Coronary Artery Disease, FFR CT Analysis, Plaque Analysis, Medical Technology, AI, Computational Fluid Dynamics, CCTA, Healthcare